som cv 050217.docx · web viewin practice based learning medical student classes, i prefer to ask...

Faculty NameP a g e | 1

UNIVERSITY OF KANSAS SCHOOL OF MEDICINEAcademic Curriculum Vitae

Please consult the CV Guidelines and APT webpage with any questions. Or mail [email protected].

Date March 2017

I. PERSONAL DATA :

1. Applicant Information:

Full Name Sufi M. Thomas Degree(s) PhD

Current Academic Rank Associate Professor

Primary Department Otolaryngology and Cancer Biology

Secondary Department Cancer Biology, and Anatomy and Cell Biology

Office Address 4031 Wahl Hall East

Office Phone 913-588-6664 Mailstop 3040

2. Professional Development :

A. Undergraduate and Graduate Education:Years (inclusive) Degree Institution

1992 BS (Life Sciences) Bombay University, India1994 MS (Life Sciences – Biotechnology) Mumbai University, India

B. Postgraduate Education:Years (inclusive) Degree Institution

2000 PhD (Applied Biology) Mumbai University, India

C. Continuing Education: Taken by applicant, such as any CME, Interprofessional Development, Doctors as Educators, Leadership Development, etc.

Year(s) Course Title Description2016 Doctors as Educators Phase II, learnt new teaching techniques including

flipped classrooms and small groups

D. Academic and Professional Appointments and Activities:

University of Kansas School of Medicine Curriculum VitaeUpdated February 29, 2016

Format updated 2-2016 lj

http://www.kumc.edu/Documents/somfacaffairs/2014%20CV%20Instructions.pdf

mailto:[email protected]

http://www.kumc.edu/school-of-medicine/faculty-affairs-and-development/appointments-promotion-and-tenure/applying-for-promotion.html

http://www.kumc.edu/school-of-medicine/faculty-affairs-and-development/appointments-promotion-and-tenure/applying-for-promotion.html#CV


Month and Year Position Institution1993 Research training in Molecular

Biology, Cytogenetics LaboratoryBanaras Hindu University, UP, India

1994-2000 PhD, Genetic Engineering Unit, Cancer Research Institute

Mumbai University, Mumbai, India

2000-2004 Research Associate, Department of Otolaryngology

University of Pittsburgh Medical Center

2004-2013 Research Assistant Professor, Department of Otolaryngology


2012-2013 Secondary Appointment in the Department of Pharmacology and Chemical Biology

University of Pittsburgh

2013-present Associate Professor, Department of Otolaryngology

University of Kansas Medical Center, Kansas City, KS, USA

2013-present Secondary Appointment in the Department of Cancer Biology


2013-present Associate Member, Cancer Biology Program


2014-present Secondary Appointment in the Department of Anatomy and Cell Biology

Kansas University Medical Center, Kansas City, KS, USA

2014 Doctors as Educators Course University of Kansas Medical Center, Kansas City, KS, USA

2014 Jayhawk Way: A pathway to excellence, Leadership training program

University of Kansas Medical Center & The Carden Group, Kansas City, KS, USA

2015 WIMS Networking and Career Development Series: The Elevator Speech and the Tweet


2016 WIMS Circle Group for Associate Professors, Co-Leader


E. Professional Registration/Licensure:Year(s) Number State

F. Professional Certification(s):Year(s) Board

G. Professional Societies and Affiliations: Year(s) Organization

2003-present American Association for Cancer Research

2005-present American Society for Cell Biology

2005-2013 University of Pittsburgh Cancer Institute

2013-present University of Kansas Cancer Center

2016-present American Head and Neck Society

H. Honors and Awards: Year(s) Award

1994 Cancer Research Fellowship, Mumbai, India




1998 Lady Tata Memorial Trust Scientific Research Scholarship, Mumbai, India

1998 Senior Research Fellowship awarded by the Council of Scientific and Industrial Research, India

2002 Lung cancer Specialized Programs of Research Excellence (SPORE) post-doctoral fellowship, University of Pittsburgh Cancer Institute, Pittsburgh, PA

2005 National Cancer Institute Fellowship to attend the Tumor Microenvironment Workshop at the laboratory of Dr. Mina Bissell, Lawrence Berkeley National Laboratory, Berkeley, CA

2014 University of Kansas Medical Center Research Institute Travel Award

2014 University of Kansas Medical Center Student Research Training Program Award (Mentee Ms. Zoe Raglow, Medical Student, University of Kansas Medical Center)

2014 Department of Otolaryngology, Alumni Day Award for Best Resident Research Presentation (Mentee Dr. Chris Kandl, 3rd year resident.)

2015 Kansas-IDeA Network of biomedical research excellence (K-INBRE) Post-Doctoral Aware (Mentee Dr. Dhruv Kumar)

2015 University of Kansas Medical Center Student Research Training Program Award (Mentee Mr. Wade Gutierrez, 3rd year Undergraduate at Kansas State University, Manhattan, Kansas)

2016 University of Kansas Medical Center Student Research Training Program Award (Mentee Ms. Vusala Shnayder, 1rd year Undergraduate at Kansas State University, Manhattan, Kansas)

2016 Vusala Shnayder, 1st place poster award, Starr Poster Contest, Association of Women Surgeons (AWA), poster titled, “Characterization of DCLK1 as a Stem Cell Marker for Head and Neck Squamous Cell Carcinoma”

2016 University of Kansas Medical Center Research Institute Travel Award

2016 1st Place Overall Oral Presentation to Jacob New-Student Research Forum-University of Kansas Medical Center

2016 Women in Medicine & Science-1st Place, Outstanding Poster Presentation to Jacob New-University of Kansas Medical Center

2017 Jacob New, Biokansas Best Poster Award, poster titled, “Secretory Autophagy in Tumor Associated Fibroblasts Promotes Head and Neck Squamous Cell Carcinoma Progression and Emerges as a Novel Therapeutic Target”. Poster presented at the 13th Annual Capitol Graduate Research Summit, Topeka, KS

2017 Jacob New, KUMC Best Poster Award, poster titled, “Secretory Autophagy in Tumor Associated Fibroblasts Promotes Head and Neck Squamous Cell Carcinoma Progression and Emerges as a Novel Therapeutic Target”. Poster presented at the 13th Annual Capitol Graduate Research Summit, Topeka, KS

II. TEACHING ACTIVITIES : Teaching evaluations and other evidence of quality teaching must be provided and should accurately summarize ALL of your teaching activities. The absence of teaching evaluations may adversely affect your application for Promotion and/or Tenure. You may ask peers to evaluate your teaching. Peer evaluation information may be found here.

1. Philosophy of Teaching: Briefly describe your philosophy of teaching and how you apply it to different types of learners (i.e. medical students, graduate students, residents, and fellows).

My objective as a teacher is to communicate complex ideas in a lucid manner without oversimplification. The best teachers are ones that involve students in an active learning process. I am a firm believer in encouraging students to give presentations, develop hypothesis and write research proposals. This facilitates critical thinking, problem solving skills and generates interest in the field. I enjoy using various teaching aids including videos, images and even the whiteboard to get the message across. In practice based learning medical student classes, I prefer to ask open ended questions to facilitate critical thinking. I encourage the students to use electronic resources to discover answers and encourage them to articulate questions no matter how trivial they may seem.



http://www.kumc.edu/Documents/somfacaffairs/Peer%20Eval%20Form%207.1.14.docx



It is highly rewarding to have taught students who imbibe a passion for the subject or who demonstrate a positive change in their world view having matured through the rigors of scientific thinking. I consider it a privilege to inspire and impact the life of another person in a positive way.

2. Instruction: A. Didactic: (i.e. lectures, grand rounds, and formal presentations)

Academic Year

Title and Course Number

Lecture or Presentation

Title

Instruction Learner

Type

Hours (actual

instruction)Number of Learners

Type of Learner(s) (i.e. medical & grad students,

residents)2007 Department of

Otolaryngology Head and Neck SPORE meeting

EGFR antisense GPNA as a therapeutic target for HNSCC

Formal Presentation

1 n/a

2008 Lung and Thoracic Malignancies Program meeting

Targeting the Epidermal Growth Factor Receptor with Antisense Guanidinium Peptide Nucleic Acid

Formal Presentation

1 n/a

2009 Department of Otolaryngology Head and Neck SPORE meeting

Head and Neck Cancer Preclinical Models

Formal Presentation

1 n/a

2010 Eye and Ear Foundation Scientific Advisory Meeting

Targeting the epidermal growth factor receptor with antisense guanidinium, peptide nucleic acids

Formal Presentation

1 n/a

2011 Fourth International Symposium on Translational Cancer Research: Recent developments in cancer prevention

Cross-talk between head and neck cancer cells and stromal fibroblasts facilitates tumor progression

Formal Presentation

1 n/a

2012 University of Texas EGFR antisense gene therapy: Progress toward systemic delivery

Formal Presentation

1 n/a

2012 Department of Pharmacology and Chemical Biology Seminar Series, University of Pittsburgh

EGFR antisense gene therapy: Progress toward systemic delivery

Formal Presentation

1 n/a




2012 Department of Otolaryngology, University of Kansas Medical Center

Deviant Stroma-Facilitators of head and neck cancer progression

Formal Presentation

1 n/a

2013 Department of Otolaryngology, University of Rochester Medical Center

Deviant Stroma-Facilitators of head and neck cancer progression

Formal Presentation

1 n/a


Demystifying Translational Research

Grand Rounds 1 hour n/a

2013 Department of Pharmacology, Toxicology, University of Kansas Medical Center

Antisense Gene Therapy Using Guanidinium Peptide Nucleic Acid Oligomers

Formal Presentation

1 hour n/a

2013 Cancer Biology Monthly Meeting, University of Kansas

The role of tumor-associated fibroblasts in head and neck cancer progression

Formal Presentation

1 hour n/a

2014 University of Kansas Cancer Center, Cancer Biology Program Meeting

Intratumor-heterogeneity of head and Neck Cancer

Formal Presentation

15 min ~70 Faculty

2014 University of Kansas Cancer Center, Cancer Biology Program Meeting

Head and neck Cancer: A True Team Player

Formal Presentation

1 hour ~30 KUMC faculty

2014 Head and Neck Cancer Interest Group

Head and Neck Cancer Research: An Overview

Formal Presentation

30 min ~30 KUMC faculty, residents and students

2014 Department of Otolaryngology, Resident Conference

Research Design and Writing Manuscripts

Formal Presentation

30 min ~25 Residents and faculty

2014 KUMC Head and Neck Cancer Support Group

Head and Neck Cancer Research: Finding the right hammer to crack a tough nut

Formal Presentation

1 h ~40 Head and Neck Cancer Survivors

2014 2014 Kansas IDeA Network of Biomedical Research Excellence (K-INBRE)

Tumor-associated Fibroblasts: The New Target for Cancer

Formal Presentation

20 min <500 Faculty and undergraduate students




Symposium Treatment

2014 Department of Anatomy and Cell Biology, University of Kansas Medical Center

Tumor-associated Fibroblasts: The New Target for Cancer Treatment

Formal Presentation

1 hour ~50 Faculty and students

2014 University of Kansas Cancer Center, Clinical Research and Translational Meeting

Promising Molecular Targeted Therapies for Head and Neck Cancer

Formal Presentation

1 hour ~50 Faculty

2014 Doctors as Educators

Angiogenesis Lecture 10 min 15 Faculty

2014 Carcinogenesis & Cancer Biology

(PHCL 969-PTOX939-PATH939-BIOL 701)

Mechanisms of Angiogenesis

Lecture 2 ½ hours 8 Graduate students

2014 Molecular Mechanisms of Neurological Diseases (NURO 848)

Brain Tumors Lecture

Paper Discussion

2 ½ hours

2 ½ hours

3 Graduate students

2014 Mechanisms of tumor development and progression (CBIO-800)

The Role of Tumor Associated Stroma in Head and Neck Cancer Progression

Lecture

Paper Discussion

2 ½ hours

2 ½ hours

4 Graduate students





2016 Molecular Mechanisms of Neurological Diseases (NURO 848)

Brain Tumors Lecture

Paper Discussion

2 ½ hours

2 ½ hours

8 Graduate students

2016 Mechanisms of tumor development and progression (CBIO-800)

The Role of Tumor Associated Stroma in Head and Neck Cancer Progression

Lecture

Paper Discussion

2 ½ hours

2 ½ hours

10 Graduate students

2016 Cellular and Molecular Mechanisms of Signal Transduction in Cancer(CBY 820)

Ras-Gap Signaling

Lecture

Paper Discussion

45 min

1 h

4 Graduate students








2017 Cellular and Molecular Mechanisms of Signal Transduction in Cancer(CBY 820)

Ras-Gap Signaling

Lecture

Paper Discussion

45 min

1 h

8 Graduate students

B. Non-didactic: (i.e. workshops, labs, seminars, discussion groups, or journal clubs)

Academic Year

Title and Course

Number Presentation

Title

Instruction Learner

Type

Hours(actual

instruction)Number of Learners

Type of Learner(s)(i.e. medical & grad students,

residents)2014 Practice

Based Learning

Small group 12 hours 9 Medical Students, Year 2

2015 Practice Based Learning

Small group 12 hours 9 Medical Students,

Year 1

2016-2017 Practice Based Learning

Small group 12 hours 9 Medical Students,

Year 2

2016 CBCL Small group 14 hours 9 Medical Students,

Year 1

C. Clinical: (i.e. clerkship, rounding, clinic, daily supervision, teaching)

Academic Year

Instruction Learner Length of Service

(i.e. 8 weeks x 6 clerkships/yr; 40 hrs/wk x 6 wks)Type Hours

Number of Learners

Type of Learner (i.e. medical students,

residents, fellows)

n/a

D. Master’s Theses and PhD Dissertations Directed: (List only those for which you are/were primarily responsible.)Year Student Name Thesis Title Degree (completed/in progress)

2015-present Jacob New Autophagy in head and neck cancer

MD, PhD, In Progress

2016-present Levi Arnold Efficacy of GZ17 in brain tumors MS, In Progress

2017 Jonathan Enders NK cell therapy in HNSCC PhD, In Progress

E. Supervision of Residents and/or Postdoctoral Fellows: List only those for which you are/were primary supervisor.

Year Resident/Fellow Name Area of Study2013-2014 Shary Shelton, PhD Tumor-associate fibroblasts in head and neck cancer

2014-present Vikalp Vishwakarma, PhD Antisense oligomers in head and neck cancer therapy




2014-2016 Dhruv Kumar, PhD Radiation-induced fibrosis in head and neck cancer

2016 Joel Jones, MD Genomics of Juvenile Nasopharyngeal Angiofibroma

2016 Sreeya Yalamanchali, MD Radiation-induced fibrosis in head and neck cancer

2016 Tran Le, MD Molecular targeting of Juvenile Nasopharyngeal Angiofibroma

Sufi M Thomas, PhDDepartment of Otolaryngology Resident Teaching Evaluations

Scale

Academic Year

Low 1 & 2Average 3 & 4High 5Can't Evaluate CENo Evaluation Returned NAYear 2014 2015 2016Breadth of Knowledge 5.00 4.67 4.67Teaching Ability 5.00 4.50 4.33Availability 5.00 5.00 4.67Academic Interest 5.00 4.67 4.67Concern for Performance 5.00 4.67 4.67Overall Contribution 5.00 3.33 4.50Research Orientation 5.00 4.83 4.67Stimulates Interest 5.00 4.83 4.67Conference/Lectures 5.00 3.20 4.50Number of Evaluations 3.00 6.00 3.00

F. Advising: Thesis or dissertation committees; student academic group/individual.Date Student or Group Name Type of Student/Group

2001-2004 Francesca Coppelli Medical Student, University of Pennsylvania

2002 Allison Ford, MD Resident, Department of Otolaryngology

2004-2005 Gina Howell Medical Student, University of Pittsburgh

2005-2006 Phoebe N Handler High School senior

2005-2006 Hiroshi Nozawa, DDS Assistant Professor, National Defense Medical College

Jul 2006 Anca Dragulescu-Andrasi Graduate Student (PhD), Carnegie Melon University

2006-2008 Shinsuke Suzuki, MD Assistant Professor, Akita University School of Medicine

2007 Ashish Gupta Graduate School of Public Health, University of Pittsburgh

2007 Janet Gonzales Medical Student, University of Pittsburgh

2007-2008 Mark Sharfinski Medical Student, University of Pittsburgh

2008 Eva Procopio Undergraduate, University of Florida

Sept 2008 Gaofei He Graduate Student (PhD), Carnegie Melon University

2008-2010 Andre Cassell Medical Student, University of Pittsburgh

2009 Joseph Kim Medical Student, University of Pittsburgh




2009 Joseph Bednash Medical Student, University of Pittsburgh

2009-2012 Guqing He, MD Visiting Scholar, China

2009-2010 Howard S Moskowitz, MD Sulindac in HNSCC Resident, Department of Otolaryngology

2010 Rachel Arffa, MD HNSCC Resident, Department of Otolaryngology

2010-2011 Jessica Maxwell Resident, Department of Otolaryngology

2010-2011 Jessica Lee Medical Student, Doris Duke Fellow, University of Pittsburgh

2011-2013 Fangchen Lin Undergraduate, University of Pittsburgh

2012-2013 Sumana Dasari Undergraduate, University of Pittsburgh

2012-2013 Sara Viragova Undergraduate, University of Pittsburgh

2012-2013 Mark Cinquegrani Undergraduate, University of Pittsburgh

Jul 2012 Jesse D Troy Graduate Student (PhD), University of Pittsburgh

Jun 2013 Fei Ding Graduate Student (PhD), University of Pittsburgh

2013-2014 Levi Ledgerwood, MD Head and Neck Fellow, Department of Otolaryngology, University of Kansas Medical Center

2013-2014 Joel Jones, MD Resident, Department of Otolaryngology, University of Kansas Medical Center

2013-2014 Nina Lu, MD Resident, Department of Otolaryngology, University of Kansas Medical Center

2013-2014 Tommy Muelleman, MD Resident, Department of Otolaryngology, University of Kansas Medical Center

2013-2014 Michael Tetwiller Medical Student, University of Kansas Medical Center

2013-2014 Chase Hamilton Volunteer, University of Kansas Medical Center

2014 Chris Kandl, MD Resident, Department of Otolaryngology, University of Kansas Medical Center

2014 Zoe Raglow Medical Student, 1st Year, University of Kansas

2014 Jacob New MD PhD Student, 1st Year, Department of Anatomy and Cell Biology

2014 Erica Chang High School, Olathe High School, Shadowing

2014 Natalie New Freshman, K State University, Shadowing

2014 Vusala Snyder Medical Student, 1st Year, KCUMB

2014 Sean Parsel Medical Student, 3rd Year, KCUMB

2015 Kyle Crooker Volunteer, 1st Year, Masters in Health Services Administration, University of Kansas Medical Center

2015 Wade Gutierrez K-State Undergraduate, awarded University of Kansas Cancer Center Summer student fellowship for HNSCC metabolism project

2015 Mark Spaw Volunteer, 3rd Year Medical Student, UMKC




2015 Levi Arnold Volunteer

2016 Joel Jones Resident, ENT

2016 Megha Ananth Summer Rotation, 1rd Year Medical Student, KUMC

2016 Shireen Usman Volunteer, 1rd Year Medical Student, KUMC

2016 Vusala Shnayder Volunteer, 1rd Year Medical Student, KUMC

2016 Emily Nissen Parker B Fellowship Summer Training Fellow, Undergraduate at Rockhurst University

2016 Tran Le Resident, ENT

2016 Sreeya Yalamanchali Resident, ENT

2017 Erina McKinney Summer Rotation, 1rd Year Medical Student, KUMC

2017 Rana Aliani Summer Rotation, 1rd Year Medical Student, KUMC

2017 Lydia Ganaden Parker B Fellowship Summer Training Fellow, University of Arkansas

2017 Mackenzie Thornton

2017

G. Other Teaching Activities: (CME and Faculty Development Seminars)Date Title of Presentation Location Teaching Function Type of Learner

02/2014 Research Design and Writing Publications

3rd Floor Sudler Conference Room, Department of Otolaryngology

Resident Research Conference

Residents

06/2015 Non-Parametric Tests 3rd Floor Sudler Conference Room, Department of Otolaryngology


Residents

06/2016 Introduction to Biostatistics

3rd Floor Sudler Conference Room, Department of Otolaryngology


Residents

3. Development of Educational Materials: Educational materials can include syllabi, educational software packages, websites, films, educational recordings, development of national examinations, and evaluation tools. Describe any process of peer-review or expert assessment to which materials have been subjected. Specifically document if the materials have been used or referenced by colleagues, at other institutions, regionally/nationally or otherwise disseminated.

Year(s) Title/Description Intended Audience

4. Educational Leadership: Describe administrative responsibility for courses and other leadership activities, including formal mentoring of junior faculty – listing names of those mentored and your role as mentor. Letters from mentees may be included.

Year(s) Name/Course/Activity Description/Role (course info, mentoring, other leadership)




III. SERVICE ACTIVITIES : See Guidelines for Promotion and Tenure, available online, for definitions and suggested documentation of service activities.

1. Clinical Service (Patient Care) Measures of both quantity and quality of activities are required. Brief descriptions to assist non-clinical reviewers are recommended. Measures of patient care activities can include: For quantity – tables or graphs demonstrating number of patients, time allocation in clinical activity, procedures

completed, Relative Value Units (RVUs), etc. (These may be included in this document or as attachments.) For quality – patient surveys/reviews or other documentation describing the value of applicant’s clinical service for

the School. If the primary quality evaluation is the subjective assessment of peers, this should be demonstrated in the letters from departmental colleagues, chair, and referees.

N/A

2. Service (Not Patient Care) Professional Service: task forces, committees (e.g. Via Christi, KU Hospital, University of Kansas Physicians), and similar groups should be explained and your specific role clarified. Categorize activities according to national, international, state and regional service. Professional consulting services must have academic credibility, clear service intent, and not be performed primarily for personal profit.

Academic Service: contributions to the academic community. Please provide names and dates of committees, task forces, or working groups. A brief description of your role and the significance of the group should be provided. Activities related to University of Kansas School of Medicine Academic Societies should be documented in this section.

List chronologically, oldest to newest.

Year(s) Committee/Task Force/Community Service/Society/Other

Role and Description(e.g. member/chair, planned the annual meeting, etc.)

International and National Service2010 American Head and Neck Society Interviewer for American head and neck society fellowship

candidates2010-2013 University Of Pittsburgh School Of

Medicine Interviewing CommitteeMember of the University Of Pittsburgh School Of Medicine Interviewing Committee

2011 French National Cancer Institute Scientific Reviewer for French National Cancer Institute2012 Judging Responsibilities Grand Awards Judge at Intel International Science and Engineering

Fair, Pittsburgh, PA2012 Judging Responsibilities Judge at Pittsburgh Region Science and Engineering Fair,

Pittsburgh, PA2013 Judging Responsibilities Judge at Pittsburgh Region Science and Engineering Fair,

Pittsburgh, PA2013 American Head and Neck Society Interviewer for American head and neck society fellowship

candidates, Pittsburgh, PA2014 Centers of Biomedical Research

Excellence (COBRE), North Dakota State University

Scientific Reviewer for Center for Protease Research, Centers of Biomedical Research Excellence (COBRE), North Dakota State University

2015 Swiss Cancer League Scientific Reviewer for Swiss Cancer League, Berne, Switzerland2011-2012 Department of Otolaryngology,

University of Kansas Medical CenterEditorial Board Member, Otolaryngology

2012-present Department of Oral Oncology, University of Kansas Medical Center

Editorial Board Member, Oral Oncology

2006-present Journal Reviewer Ad-Hoc Reviewer, Head and Neck



http://medicine.kumc.edu/Documents/somfacaffairs/KUSOMGuidelinesforPromotionandTenure.pdf



2006-present Journal Reviewer Ad-Hoc Reviewer, Current Cancer Drug Targets2007-present Journal Reviewer Ad-Hoc Reviewer, Oncology2007-present Journal Reviewer Ad-Hoc Reviewer, Molecular Carcinogenesis2007-present Journal Reviewer Ad-Hoc Reviewer, International Journal of Cancer2008-present Journal Reviewer Ad-Hoc Reviewer, Biomed Central2008-present Journal Reviewer Ad-Hoc Reviewer, Clinical and Experimental Metastasis2008-present Journal Reviewer Ad-Hoc Reviewer, Clinical Cancer Research2008-present Journal Reviewer Ad-Hoc Reviewer, Journal of Cancer Research and Clinical

Oncology2009-present Journal Reviewer Ad-Hoc Reviewer, Investigational New Drugs2009-present Journal Reviewer Ad-Hoc Reviewer, Translational Oncology2010-present Journal Reviewer Ad-Hoc Reviewer, Oncogene2010-present Journal Reviewer Ad-Hoc Reviewer, Cancer Research2010-present Journal Reviewer Ad-Hoc Reviewer, The Open Otorhinolaryngology Journal2011-present Journal Reviewer Ad-Hoc Reviewer, Cancer2011-present Journal Reviewer Ad-Hoc Reviewer, Melanoma Research2011-present Journal Reviewer Ad-Hoc Reviewer, International Journal of Nanomedicine2011-present Journal Reviewer Ad-Hoc Reviewer, Oral Oncology2012-present Journal Reviewer Ad-Hoc Reviewer, PLOS ONE2012-present Journal Reviewer Ad-Hoc Reviewer, Tumor Biology2012-present Journal Reviewer Ad-Hoc Reviewer, Biochemical Pharmacology2012-present Journal Reviewer Ad-Hoc Reviewer, Molecular Cancer Therapeutics2013 Department of Otolaryngology,

University of Kansas Medical CenterInterviewed Head and Neck residents at the Department of Otolaryngology, University of Kansas Medical Center, Kansas City, KS

2013-present Department of Otolaryngology, University of Kansas Medical Center

Interviewed Head and Neck residents at the Department of Otolaryngology, University of Kansas Medical Center, Kansas City, KS

2014-present Journal Reviewer Ad-Hoc Reviewer, Cancer Letters2014-present Journal Reviewer Ad-Hoc Reviewer, Journal of Visualized Experiments2015-present Journal Reviewer Ad-Hoc Reviewer, World Journal of Gastroenterology2015-present Journal Reviewer Ad-Hoc Reviewer, International Journal of Medical Sciences2015-present Journal Reviewer Ad-Hoc Reviewer, Systems Biology and Medicine2016-present Journal Reviewer Ad-Hoc Reviewer, Molecular Carcinogenesis2016 National Science Center, Poland Scientific Reviewer 2016 Swiss Cancer League Scientific Reviewer2016 Leid Pilot Award Scientific Reviewer2016 KUCC, Pilot Awards Scientific ReviewerRegional, State, and Local Service2014 Judging Responsibilities Faculty Judge, 5th Annual Resident, Postdoc and Fellow Research

Forum, University of Kansas Medical Center, Kansas City, KS2014 Judging Responsibilities Faculty Judge, Student Research Forum, University of Kansas

Medical Center, Kansas City, KS2015-present Judging Responsibilities Faculty Judge, Student Research Forum, University of Kansas

Medical Center, Kansas City, KS2015-present Judging Responsibilities Faculty Judge, 6th Annual Resident, Postdoc and Fellow Research

Forum, University of Kansas Medical Center, Kansas City, KS2015-present Judging Responsibilities Faculty Judge, 3rd Annual Women In Medicine & Science Poster

Session, University of Kansas Medical Center, Kansas City, KS2015-present Judging Responsibilities Judge, Poster Session, University of Kansas Cancer Center

Symposium2015-present University of Kansas Cancer Center Reviewer for University of Kansas Cancer Center Pilot AwardsKUMC, School of Medicine, and Departmental Service2014-present Department of Otolaryngology,

University of Kansas Medical CenterResident Research Committee, Department of Otolaryngology-Head & Neck Surgery: As a part of this committee I oversee the resident research rotations within the Department.

2014-2015 Department of Otolaryngology, University of Kansas Medical Center

Organized the Head and Neck Cancer Interest Group Seminar Series, University of Kansas Medical Center, Kansas City, KS


Program Evaluation Committee, Department of Otolaryngology, University of Kansas Medical Center




IV. RESEARCH AND SCHOLARLY ACTIVITIES :

1. Opening Statement:

Provide a brief opening statement to explain the principal areas of scholarly activity and provide your perspective. A description of your most significant contributions to the literature is often helpful to the reviewers.

2. Grants, Contracts and Clinical Trials: Include names of all investigators (applicant’s name in bold) and if co-investigator, specify applicant’s role. Also include the title of grant, funding source, dollar amount in direct costs, and inclusive years of grant award. Provide the cover sheet, abstract, or Notice of Award in PDF for all grants or contracts awarded in last five years.

All entries in this section should be listed in chronological order, oldest to newest. Be sure to list applicant’s name in BOLD.

A. Previous Grants, Contracts, and Clinical Trials

Principal Investigator Investigators

Title of Grant/Contract/Trial

Funding Source

Direct Costs/

Funding

Inclusive Years of Award Status

Dr. Jill Siegfried Dr. Sufi Thomas Intersection of Estrogen Receptor Signaling and Epidermal Growth Factor Receptor Signaling in Lung Cancer

NIH - 5P50 CA090440-08S1

2001-2011 Complete

Dr. Jill Siegfried Dr. Sufi Thomas Specialized Program of Research Excellence (SPORE) in Lung Cancer

NCI 2002-2003 Complete

Dr. Jennifer Grandis

Dr. Sufi Thomas Specialized Program of Research Excellence (SPORE) in Head and Neck Cancer Project 4: Targeting EGFR and GPCR Signaling in SCCHN.The goal of this program is to improve the prevention, detection and treatment f head and neck cancer through translational research.

NCI – 1 P50 CA097190-01A1

2004-2009 Complete


Dr. Sufi Thomas GRPR Signaling in SCCHN: Integration with EGFR

NIH/NCI – 5 RO1 CA098372-03

2004-2009 Complete

Dr. Dong Shin Dr. Sufi Thomas Chemoprevention of HNC with Erlotinib & Celecoxib

NIH/NCI – 1 U01 CA 101244-01

2004-2009 Complete

Dr. Sufi Thomas Combined inhibition of EGFR and GPCR autocrine signaling in head and neck squamous cell carcinoma

Imclone Systems

2005-2006 Complete


Dr. Sufi Thomas Targeting STAT3 using STAT3 decoy and antisense oligonucleotides in head and neck cancer

Eli-Lilly Incorporated

2005-2006 Complete





Dr. Robert Ferris Dr. Sufi Thomas Chemokine Signals in Head and Neck Cancer Progression

NIH/NCI – 1 R01 CA115902-01

2006-2011 Complete

Dr. Danith Ly Dr. Sufi Thomas Development of a Second Generation Cell-Permeable GPNA

Applied Biosystems Incorporated

2006-2008 Complete

Dr. Sufi Thomas Developmental Research Project, Specialized Program of Research Excellence (SPORE) in Lung Cancer Targeting EGFR in lung cancer with EGFR guanidinium antisense peptide nucleic acids


Dr. Marcus Marpara

Dr. Sufi Thomas Role of STAT1 and STAT3 in Graft versus Host Disease and Graft versus Leukemia effects

1RO1 HL093716 01A1

2008-2013 Complete

Dr. Ethan Argiris Athanassios

Dr. Sufi Thomas EGFR Antisense DNA NCI - 1 R21CA130241

2008-2010 Complete

Dr. Jian Yu Dr. Sufi Thomas Role of PUMA in the EGFR targeted therapy in HNSCC

NIH – 1RO1 CA129829

2008-2013 Complete

Dr. Dan Johnson Dr. Sufi Thomas Molecular Targeting Strategies in HNSCC

NIH/NCI – 1 R01 CA137260

2010-2015 Complete

Dr. Sufi Thomas The role of tumor-associated fibroblasts in head and neck cancer progression


2011-2013 Complete

Dr. Bennett Van Houten

Dr. Sufi Thomas Developmental, Research Project, Specialized Program of Research Excellence (SPORE) in Head and Neck Cancer Metabolic symbiosis: a new therapeutic target in head and neck tumors


B. Current Grants, Contracts, and Clinical Trials



Funding Source

Direct Costs/

Funding


Dr. Sufi Thomas Start-up funds Department of Otolaryngology

2013-2016 In Progress

Dr. Sufi Thomas Intratumor-heterogeneity of head and neck cancer

University of Kansas Cancer Center, Cancer Biology Program Pilot Award

$6000 2014-2015 Completed

Dr. Sufi Thomas Optimization of GZ17 as a novel therapeutic agent for head and neck cancer

Likarda, LLC Sponsored Research

$80,000 2014-2016 Completed




Agreement

Dr. Sufi Thomas In silico analysis of GZ17-6.02-components and in vivo antitumor efficacy in head and neck cancer preclinical models

Likarda, LLC Sponsored Research Agreement

$100,000 2015-2016 In Progress

Dr. Sufi Thomas Targeting mutant EGFR in glioma

University of Kansas Cancer Center

$35000 2015-2016 Completed

Dr. Sufi Thomas Drs. Shnayder and Dai

Role of tumor-associated fibroblasts in head and neck cancer metabolism

American Head and Neck Society

$10,000 2016-2017 Awarded

C. Submitted Grants, Contracts, and Clinical Trials (include all grants, contracts, and clinical trials submitted, even if unfunded)



Funding Source

Direct Costs/

Funding


Dr. Sufi Thomas Dr. Danith Ly Mutation-specific guanidinium peptide nucleic acid for cancer therapy

National Cancer Institute

$1,365,450 2016-2021 Scored

Dr. Sufi Thomas Assessing the role of TAFs in Anal Carcinoma

O’Sullivan Foundation

$30,000 2017-2018 Funded

Dr. Sufi Thomas Dr. Shrikant Anant

Targeting Stemness in Head and Neck Squamous Cell Carcinoma

NCI, RO1 $1,247,286 2016-2022 Scored

Dr. Sufi Thomas Testing natural compounds in HNSCC

Genzada Inc $300,000 2016-no end Under Review

Dr. Sufi Thomas Tumor-associated fibroblasts in head and neck cancer metabolism and progression

COBRE Pilot Project

$ 449,999 2017-2020 Pending award notification

Dr. Sufi Thomas Tumor-associated fibroblasts in head and neck cancer metabolism and progression

Leid Pilot Grand

$ 25,000 2017-2018 Not funded

Dr. Tomoo Iwakuma

Dr. Sufi Thomas Control of mutant p53 stability via the mevalonate pathway-DNAJA1 axis

NIH/NCI R01CA214916

$1,247,286 2017-2022 Pending award notification

3. Scholarly Publications: Publications must be numbered in chronological order, oldest to newest. In cases where there are multiple publications within a year, they should be listed in alphabetical order.

A PDF of each published article/manuscript/paper/review, completed within the last five years, is required. If a link to the article online and/or a PubMed ID is included with citation below, a PDF is not required. Additional articles may be provided at the applicant’s discretion. Information regarding accepted citation styles can be found here.

A. Articles (Peer-Review Published):



http://guides.library.kumc.edu/content.php?pid=625417&sid=5173103


Include full-length, peer-reviewed articles in scientific journals. List all authors (applicant’s name in BOLD), year, title, journal, volume, and inclusive pages.

Do not include papers in preparation, submitted, or under revision, nor should it include conference proceedings, published abstracts, or book reviews (which are listed separately).




Mulherkar R, Goud AP, Wagle AS, Naresh KN, Mahimkar MB, Thomas SM, Pradhan SA, Deo MG. Establishment of a human squamous cell carcinoma cell line of the upper aero-digestive tract. Cancer Letters 1997, 118 (1): 115-121. PMID: 9310268Thomas SM, Naresh KN, Wagle AS, Mulherkar R. Preclinical studies on suicide gene therapy for Head/neck cancer: a novel method for evaluation of treatment efficacy. Anticancer Research 1998, 8 (6): 4394-4398. PMID: 9891498Thomas SM, Zeng Q, Dyer K, Suscovich1 TJ, Kanter PM, Watkins SF, Grandis JR. Tissue distribution of liposome-mediated epidermal growth factor receptor antisense gene therapy. Cancer Gene Therapy 2003, 10 (7): 518-527. PMID: 12833132Lui VWY*, Thomas SM*, Zhang Q, Wentzel AL, Siegfried JM, Li JY, and Grandis JR. The mitogenic effects of gastrin-releasing peptide in head and neck squamous cancer cells are mediated by activation of the epidermal growth factor receptor. Oncogene, 2003 (22): 6183-6193. PMID: 13679857*First Co-authorThomas SM, Coppelli FM, Drenning SD, Song JI, Kassis J, Gooding WE, Wells A, Grandis JR. Epidermal growth factor receptor-stimulated activation of PLC-1 mediates invasion of head and neck squamous cell carcinoma in vitro. Cancer Research, 2003 (63): 5629-5635. PMID: 14500405Thomas SM, Grandis JR. Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treatment Reviews, 2004, 30 (149), 255-268. PMID: 15059649Thomas SM, Grandis JR. Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treatment Reviews, 2004, 30 (149), 255-268. PMID: 15059649Qing Zhang, Thomas SM, Xi S, Wentzel AL, Smithgall TE, Siegfried JM, Kamens J, Grandis JR. Src family kinases mediate epidermal growth factor receptor (EGFR) ligand cleavage and EGFR activation by gastrin releasing peptide in head and neck squamous cell carcinoma. Cancer Research, 2004, 64 (17): 6166-6173. PMID: 15342401Thomas SM, Zeng Q, Epperly MW, Gooding WE, Pastan I, Wang QC, Greenberger J, Grandis JR. Abrogation of head and neck squamous cell carcinoma growth by EGFR ligand fused to Pseudomonas exotoxin TGF--PE38. Clinical Cancer Research, 2004, 10: 7079-7087. PMID: 15501988Thomas SM, Grandis JR, Wentzel AL, Gooding WE, Lui VYW, Siegfried JM. Gastrin-releasing peptide receptor mediates activation of the epidermal growth factor receptor in lung cancer cells, Neoplasia, 2005, 7 (4): 426-431. PMCID: PMC1501149Wang J, Zhang X, Thomas SM, Grandis SM, Wells A, Chen ZG, Ferris RL. Phosphoinositide-3 kinase (PI3K) dependent chemokine receptor 7 mediated survival and invasion of head and neck cancer cells independent of EGFR. Oncogene, 2005, 24(38):5897-904. PMID: 16007209Zhang Q, Thomas SM, Lui VWY, Xi S, Siegfried JM, Fan H, Smithgall TE, Mills GB, Grandis JR. Phosphorylation of TNF- converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. PNAS, 2006, 103 (18):6901-6906. PMCID: PMC1458991Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, Bigner DD, Freilino ML, Graner MW, Wikstrand CJ, Gooding WE, Furnari FB, Grandis JR. Mutant epidermal growth factor receptor (EGFR vIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clinical Cancer Research, 2006, 12(17):5064-5073. PMID: 16951222Thomas SM, Bhola NE, Zhang Q, Contrucci SC, Wentzel AL, Freilino ML, Gooding WE, Siegfried JM, Chan DC, Grandis JR. Cross-talk between G-protein-coupled receptor and epidermal growth factor receptor signaling pathways contribute to growth and invasion of head and neck squamous cell carcinoma. Cancer Research, 2006, 66(24):11831-9. PMID: 17178880Fridman JS, Caulder E, Hansbury M, Liu X, Gu X, Pan M, Zhou BB, Yang G, Wang Q, Lo Y, Thomas SM, Grandis JR, Zhuo J, Yao W, Newton RC, Friedman SM, Scherle PA, and Vaddi K. Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer. Clinical Cancer Research, 2007, 13(6):1892-902. PMID: 17363546Zhang Q, Bhola NE, Lui VWY, Siwak DR, Xi S, Thomas SM, Gubish CT, Siegfried JM, Mills GB, Shin D, Grandis JR. Antitumor mechanisms of combined GRPR and EGFR targeting in head and neck cancer. Molecular Cancer Therapeutics, 2007, 6(4):1414–24. PMID: 17431120Thomas SM, Ogagan MJ, Freilino ML, Strychor S, Walsh DR, Gooding WE, Grandis JR, Zamboni WC. Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck. Molecular Pharmacology, 2008, 73:627-638. PMID: 18025070Miranda MB, Duan R, Thomas SM, Grandis JR, Redner RL, Jones JE, Johnson DE. Gefitinib potentiates myeloid cell differentiation by ATRA. Leukemia, Advance online publication, 2008, 22 (8) :16241-7. PMCID: PMC2596306Koppikar P, Choi S, Egloff AM, Cai Q, Suzuki S, Freilino M, Nozawa H, Thomas SM, Gooding W, Siegfried JM, Grandis JR. Combined inhibition of c-src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma. Clinical Cancer Research, 2008,14:4284-91. PMID: 18594011. PMC Journal-In ProcessNozawa H, Howell G, Suzuki S, Zhang Q, Qi Y, Klein-Seetharaman JK, Wells A, Grandis JR, Thomas SM. Combined inhibition of PLC-1 and c-Src abrogates epidermal growth factor receptor mediated head and neck squamous cell carcinoma invasion, Clinical Cancer Research, 2008,14:4336-43. PMID: 18594017. PMCID: PMC3358699Sen M, Tosca P, Zwayer C, Ryan M, Johnson J, Knostman K, Giclas P, Peggins J, Tomaszewski J, McMurray T, Li C, Leibowitz M, Ferris R, Gooding W, Thomas SM, Johnson D, Grandis JR. Lack of toxicity of a STAT3 Decoy oligonucleotide. Cancer Chemotherapy and Pharmacology, 2009, 63 (6):983-95. PMID: 18766340. PMC Journal-In ProcessLai SY, Koppikar P, Thomas SM, Childs EE, Egloff AM, Seethala RR, Branstetter BF, Gooding WE, Siwak DR, Muthukrishnan A, Mountz JM, Lui VWY, Shin DM, Agarwal SS, Johnson R, Couture LA, Myers E, Johnson JT, Mills G, Argiris A, Grandis JR. Intratumoral EGFR antisense DNA therapy in head and neck cancer: First Human application and potential antitumor mechanisms. J Clinical Oncology, 2009, 10;27(8):1235-42. PMCID: PMC2667824Zou H, Thomas SM, Yan ZW, Grandis JR, Vogt A, Li L. Human Rhomboid Family-1 Gene RHBDF1 Participates in GPCR-Mediated Transactivation of EGFR Growth Signals in Head and Neck Squamous Cancer Cells, FASEB J, 2009, 23(2):424-432.




PMCID: PMC2638965Sahu B, Chenna V, Lathrop KL, Thomas SM, Zon G, Livak KJ, Ly DH. Synthesis of conformationally preorganized and cell-permeable guanidine-based-peptide nucleic acids (GPNA), Journal of Organic Chemistry, 2009, 74:1509-1516. PMCID: PMC2650244Knowles LM, Stabile LP, Egloff AM, Rothstein ME, Thomas SM, Gubish CT, Lerner EC, Seethala RR, SuzukiS, Quesnelle KM, Morgan S, Ferris RL, Grandis JR, Seigfried JM. HGF and c-Met Participate in paracrine tumorigenic pathways in head and neck squamous cell cancer, Clinical Cancer Research, 2009, 15(11):3740-50. PMID: 19470725. PMCID: PMC3159511Thomas SM, Grandis JR. The current state of head and neck cancer gene therapy. Human Gene Therapy, 2009, 2009, 20: 1565-75. PMCID: PMC2829451Sun Q, Ming L, Thomas SM, Wang Y, Zhuo GC, Ferris RL, Grandis JR, Zhang L, Yu J. PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells, Oncogene, 2009, 28(24):2348-57. PMID: 19421143. PMCID: PMC2872091Leeman-Neill RJ, Morgan SE, Singh SV, Thomas SM, Seethala RR, Neill DB, Hahm ER, Panahandeh MC, Joyce SC, Sen M, Cai Q, Li C, Grandis JR. Guggulsterone inhibits growth of head and neck squamous cell carcinoma via targeting of Signal Transducer and Activator of Transcription-3 signaling. Carcinogenesis, 2009, 30 (11): 1848-56. PMCID: PMC2783003Benchekroun MT, Saintigny P, Thomas SM, El-Naggar AK, Papadimitrakopoulou V, Ren H, Lang W, Fan Y, Huang J, Feng L, Lee JJ, Kim ES, Hong WK, Johnson FM, Grandis JR and Mao L. Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prevention Research, 2010, 3(7):800-9. PMCID: PMC2900459Leeman-Neill R, Cai Q, Joyce S, Thomas SM, Bhola N, Neill D, Arbiser J, Grandis J. Honokiol inhibits EGFR signaling and enhances the antitumor effects of EGFR inhibitors. Clinical Cancer Research, 2010, 16(9); 2571–9. PMCID: PMC2871379Wheeler S, Suzuki S, Thomas SM, Sen M, Leeman-McNeill R, Kuan C, Bigner DD, Gooding WE, Lai S, Grandis JR. Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation. Oncogene, 2010, 16;29(37):5135-45. PMCID: PMC2940981Leeman-Neill RJ, Seethala RR, Singh S, Freilino ML, Bednash JS, Thomas SM, Panahandeh MC, Gooding WE, Joyce SC, Lingen MW, Neill DB, Grandis JR. Inhibition of EGFR-STAT3 signaling with erlotinib prevents carcinogenesis in a mouse model of oral squamous cell carcinoma. Cancer Prev Res (Phila), 2011, 4(2):230-7. PMID: 21163936. PMCID: PMC3076320Bhola NE, Thomas SM, Freilino M, Joyce S, Sahu A, Maxwell J, Argiris A, Seethala R, Grandis JR. Targeting GPCR-mediated p70S6K activity may improve head and neck cancer response to cetuximab. Clinical Cancer Research, 2011, 17(15): 4996-04. PMID: 21653688. PMCID: PMC3149755Argiris A, Lee SC, Feinstein T, Thomas S, Branstetter BF 4th, Seethala R, Wang L, Gooding W, Grandis JR, Ferris RL. Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer. Oral Oncology, 2011, 47 (10): 961-6. PMID: 21889392. PMC Journal-In ProcessBhola NE, Freilino ML, Joyce SC, Sen M, Thomas SM, Sahu A, Cassell A, Chen CS, Grandis JR. Anti-tumor mechanisms of targeting the PDK1 pathway in head and neck cancer. Molecular Cancer Therapeutics, 2012, 11 (6):1236-46. PMID: 22491800Moskowitz HS, Gooding WE, Thomas SM, Freilino ML, Gross N, Argiris A, Grandis JR, Ferris RL. Serum biomarker modulation following molecular targeting of epidermal growth factor and cyclooxygenase pathways: a pilot randomized trial in head and neck. Oral Oncology, 2012, 48 (11): 1136-45. PMID: 22732263. NIHMSID: 381064Sen M, Thomas SM, Kim S, Yeh JI, Ferris RL, Johnson JT, Duvvuri U, Lee J, Sahu N, Joyce S, Freilino ML, Shi H, Li C, Ly D, Rapireddy S, Etter JP, Li P, Wang L, Chiosea S, Seethala RR, Gooding WE, Chen X, Kaminski N, Pandit K, Johnson DE, Grandis JR. First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. Cancer Discovery, 2012, 2: 694-705. PMID: 22719020, NIHMSID: 468365. PMCID: PMC3668699Sen M, Joyce S, Panahandeh MC, Li C, Thomas SM, Maxwell J, Wang L, Gooding WE, Johnson DE, Grandis JR. Targeting STAT3 abrogates EGFR inhibitor resistance in cancer. Clinical Cancer Research, 2012, 18: 4986-96. NIHMSID: 396060, PMCID: PMC 3445706Zang Y, Thomas SM, Chan ET. Kirk CJ, Freilino ML, DeLancey HM, Grandis JR, Li C, Johnson DE. Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy. Clinical Cancer Research, 2012, 18 (20): 5639-49. PMID: 22929803, PMCID: 3473099Zang Y, Thomas SM, Chan ET. Kirk CJ, Freilino M, DeLancey HM, Grandis JR, Li C, Johnson DE. The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvivial autophagy via induction of the unfolded protein response and ATF4. Autophagy, 2012, 8 (12): 1873-4. PMID: 22995770, PMCID: PMC3541310Thomas SM. Molecular targeted therapies for head and neck cancer: A new era in DNA-based therapeutics. Editorial: Otolaryngology, 2012, 22 (3): 207-13. PMID: 22687945Cassell A, Freilino ML, Lee J, Barr S, Wang L, Panahandeh MC, Thomas SM, Grandis JR. Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models. Neoplasia, 2012, 14 (11): 1005-14. PMCID: PMC3514742Mason NS, Lopresti BJ, Ruszkiewicz J, Dong X, Joyce S, Leef G, Sen M, Wahed AS, Mathis CA, Grandis JR, Thomas SM. Utility of 3'-[18F]fluoro-3'-deoxythymidine as a PET tracer to monitor response to gene therapy in a xenograft model of head and neck carcinoma. American Journal of Nuclear Medicine and Molecular Imaging. 2012, 3 (1): 16-31. PMCID: PMC3545366Thomas SM, Sahu B, Rapireddy S, Bahal R, Wheeler SE, Procopio EM, Kim J, Joyce SC, Contrucci S, Wang Y, Chiosea SI, Lathrop KL, Watkins S, Grandis JR, Armitage BA, Ly DH. Antitumor effects of EGFR antisense guanidine-based peptide nucleic acids in cancer models. American Chemical Society, Chemical Biology. 2012, 8 (2): 345-52. PMCID: PMC3684443Shin DM, Zhang H, Saba NF, Chen AY, Nannapaneni S, Ruhul Amin ARM, Muller S, Lewis M, Sica G, Kono S, Brandes JC, Grist WJ, Moreno-Williams R, Beitler JJ, Thomas SM, Chen Z, Shin HJC, Grandis JR, Khuri FR, Chen ZG. Chemoprevention of head



http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3159511/


and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies. Clinical Cancer Research, 2013, 19 (5): 1244-56. PMICD: PMC3693760Leef G, Thomas SM. Molecular communication between tumor-associated fibroblasts and head and neck squamous cell carcinoma. Oral Oncology. 2013, 49 (5): 381-6. PMID: 23357526, PMCID: PMC3615086. NIHMS 440331Stabile LP, He G, Lui VWY, Thomas SM, Henry C, Gubish CT, Joyce S, Quesnelle KM, Siegfried JM, Grandis JR. c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met. Clinical Cancer Research, 2013, 19 (2): 380-92. PMCID: PMC3549019Wheeler SE, Shi H, Lin F, Dasari S, Bednash J, Thorne S, Watkins S, Joshi R, Thomas SM. Tumor associated fibroblasts enhance head and neck squamous cell carcinoma proliferation, invasion and metastasis in preclinical models. Head & Neck, 2013, 35. PMCID: PMC4111913.Troy JD, Weissfeld JL, Youk AO, Thomas SM, Wang L, Grandis JR, Wang L, Grandis JR. Expression of EGFR, VEGF and NOTCH1 suggest differences in tumor angiogenesis in HPV-positive and HPV-negative head and neck squamous cell carcinoma. Head and Neck Pathology, 2013, 7(4): 344-355. PMCID: PMC3824798Sok JC, Lee JA, Dasari S, Joyce S, Contrucci SC, Egloff AM, Trevelline BK, Joshi R, Kumari N, Grandis JR, Thomas SM. Collagen type Xi 1 facilitates head and neck squamous cell cancer growth and invasion. British Journal of Cancer, 2013, 109 (12): α3049-3056. PMCID: PMC3859935Gross ND, Bauman JE, Gooding WE, Denq WH, Thomas SM, Wang L, Chiosea S, Hood BL, Flint MS, Sun M, Conrads TP, Ferris RL, Johnson JT, Kim S, Argiris A, Wirth LJ, Nikiforova MN, Siegfried JM, Grandis JR. Erlotinib, erlotinib-sulindac vs. placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer. Clinical Cancer Research, 2014, 20(12): 3289-98. PMCID: PMC4104657.Roh J, Muelleman T, Tawfik O, Thomas SM. Perineural growth in head and neck squamous cell carcinoma: A review. Oral Oncology, 2014, 51(1): 16-23. PMID: 25456006, PMCID: PMC4268058.Raglow Z, Thomas SM. Tumor matrix protein collagen Xl 1 in cancer. Cancer Letters, 2014, 357(2): 448-53. PMID: α25511741, PMCID: PMC4307931.Straub JM, New J, Hamilton CD, Lominska C, Shnayder Y, Thomas SM. Radiation-induced fibrosis: Mechanisms and implications for therapy. Journal of Cancer Research and Clinical Oncology, 2015, 141(11): 1985-94. PMID: 25910988, PMCID: PMC4573901. Kumar D, Kandl C, Hamilton CD, Shnayder Y, Tsue TT, Kakarala K, Ledgerwood LG, Sun XS, Huang H, Girod D, Thomas SM. Mitigation of Tumor-Associated Fibroblast-Facilitated Head and Neck Cancer Progression With Anti-Hepatocyte Growth Factor Antibody Ficlatuzumab. JAMA Otolaryngology, 2015, 141 (12), 1133-9. PMID: 26540318, PMCID: PMC4815928.Li H, Wheeler S, Park Y, Ju Z, Thomas SM, Fichera M, Egloff AM, Lui VW, Duvvuri U, Bauman JE, Mills GB, Grandis JR. Proteomic Characterization of Head and Neck Cancer Patient-Derived Xenografts. Molecular Cancer Research, 2016, 14(3):278-86. PMID: 26685214, PMCID: PMC4794346.Ledgerwood LG, Kumar D, Eterovic AK, Wick J, Chen K, Zhao H, Tazi L, Manna P, Kerley S, Joshi R, Wang L, Chiosea SI, Garnett JD, Tsue TT, Chien J, Mills GB, Grandis JR, Thomas SM. The degree of intratumor mutational heterogeneity varies by primary tumor sub-site. Oncotarget, 2016, 7(10): 27185-98. PMCID: PMC5053641.Lui A, New J, Ogony J, Thomas S, Lewis-Wambi J. Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells. BMC cancer. 2016; 16:487. PMID: 27421652, PMCID: PMC4947349.

B. Manuscripts in Press: List all authors (applicant’s name in BOLD), title, journal, and PDF of manuscript, plus documentation of acceptance by journal. Spaw M, Anant S, Thomas SM. Stromal contributions to the carcinogenic process. Molecular carcinogenesis. 2016; PMID: 27787930, PMCID: In Process

C. Manuscripts Submitted - not yet accepted for publication:

D.

Invited or Non-Peer Reviewed Articles or Reviews: List all authors (applicant’s name in BOLD), year, title, journal, volume, and pages.

Thomas SM, Grandis JR. Targeting mesenchymal exaptation to mitigate tumor growth. Cell Cycle. 2011, 10(16): 2626-7. PMID: 21836394. PMC Journal-In ProcessThomas SM. Otolaryngology Research: A new frontier in head and neck cancer genomics. Editorial: Otolaryngology, 2011, 1:1Parsel SM, Grandis JR, Thomas SM. Nucleic acid targeting: Towards personalized therapy for head and neck cancer. Oncogene, 2016, 35 (25): 3217-26. PMID: 26592450, PMCID: PMC4877278.



List all authors (applicant’s name in BOLD), title, journal, and PDF of manuscript, plus evidence of receipt by journal.

Le T, Usman S, New J, Yalamanchali S, Jones J, Tawfik O, Hoover L, Bruegger DE, Thomas SM. Inhibition of Fibroblast Growth Factor Receptor with AZD4547 Mitigates Juvenile Nasopharyngeal Angiofibroma. The International Forum of Allergy & Rhinology Journal.


E. Books and Book Chapters: List all authors (applicant’s name in BOLD), year, book title, chapter title, edition, publisher, and pages. If in press and available online, a link to book/book chapter is recommended. A PDF is not required for books or book chapters, unless requested by Committee. Thomas SM, Rubin Grandis J. Importance of EGF Receptor in Head and Neck Cancer. Updates. 1(1) 1-11, 2001.

Thomas SM, Grandis JR. In Wells A (ed): Motility in Head and Neck Carcinoma. Cell Motility in Cancer Invasion and Metastasis. Springer, 245-264, 2006.Mathew M, Thomas SM. In Li X (ed): Squamous Cell Carcinoma. The Cellular Microenvironment of Head and Neck Squamous Cell Carcinoma, ISBN 978-953-307-864-9. In Tech, 163-174, 2012. Reese JS, Embree H, Thomas SM, Grandis JR, Gerson SL. In Gene Therapy for Cancer, 3rd edition, Lattime EC and Gerson SL (eds): Chapter 34; Issues in moving gene therapy approaches to early clinical trials. Elsevier, 493-501, 2014.Lu NG, Kakarala K, Thomas SM. Head and Neck Cancer: An Overview. Encyclopedia of Cancer, Editor Manfred Schwab, 4th Edition Springer-Verlag Berlin Heidelberg, In Press.

F. Published Abstracts: List all authors (applicant’s name in BOLD), year, title, where published, volume and pages. If the same work is reflected in a published abstract and a presentation or poster, the work must only be listed once. Additional lines may be added to published abstracts to indicate meeting and date of any oral or poster presentations.Thomas SM, Naresh KM, Wagle AS, Mulherkar R. In vitro and in vivo tumor ablation using Herpes Simplex virus thymidine kinase suicide gene mediated bystander effect in oral squamous cell carcinoma. Proceedings of Indian Association of Cancer Research Meeting, 1997. Song JI, Thomas SM, Wells A, Grandis JR. EGFR-mediated PLC-1 signaling in head and neck squamous cell carcinoma cell lines. Proceedings of the American Association of Cancer Research 42:173, 2001. Thomas SM, Coppelli FM, Drenning SD, Song JI, Kassis J, Gooding WE, Wells A, Grandis JR. Epidermal growth factor receptor-stimulated activation of phospholipase C-1 and its role in invasion of head and neck squamous cell carcinoma in vitro. Proceedings of the American Association of Cancer Research 43:542-543, 2002. Thomas SM, Coppelli FM, Drenning SD, Song JI, Kassis J, Gooding WE, Wells A, Grandis JR. Specificity of epidermal growth factor signaling via phospholipase C in invasion of head and neck squamous cell carcinoma and biological relevance in vivo. Proceedings of American Association of Cancer Research Special Conference in Cancer Research, October 2002, Hilton Head, SC. Thomas SM, Wentzel AL, Zhang Q, Siegfried JM, Grandis JR. Combined targeting of G-protein coupled receptor and the epidermal growth factor receptor signaling pathways in head and neck squamous cell carcinoma. Poster presented at AACR-NCI-EORTC International Conference, Boston, MA, Clinical Cancer Research (supplement), 9 (16): 6092S-6093S Part 2 Suppl. S, 2003. Lopresti BJ, Thomas S, Mathis CA, Mason NS, Ruszkiewicz JA, Grandis JR. Differential [F-18]FLT and [F-18]FDG uptake in murine models of human squamous cell carcinoma of the head and neck (SCCHN). Poster presented at Academy of Molecular Imaging, Orlando, FL. Molecular Imaging and Biology 6(2): 98, 2004. Qing Z, Thomas SM, Xi S, Wentzel AL, Smithgall TE, Siegfried JM, Gooding WE, Grandis JR. Src family kinases mediate epidermal growth factor receptor (EGFR) ligand cleavage and EGFR activation by gastrin releasing peptide (GRP) in head and neck squamous cell carcinoma (HNSCC). Poster presented at American Association of Cancer Research 95th Annual Meeting, Orlando, FL. Proceedings of the American Association of Cancer Research, 45:194, 2004. Thomas SM, Lui VWY, Wentzel AL, Grandis JR, Siegfried JM. Gastrin-releasing peptide-mediated activation of epidermal growth factor receptor in lung cancer. Poster presented at American Association of Cancer Research, 95th Annual Meeting, Orlando, FL. Proceedings of the American Association of Cancer Research, 45:188, 2004. Zhang Q, Xi S, Thomas SM, Ogagan MJ, Siegfried JM, Fan H, Smithgall TE, Kamens J, Mills GB, Grandis JR. Src and P13 kinase mediated TACE activation contributes to GRP-induced EGFR signaling in SCCHN. Proceedings of the American Association of Cancer Research 46:145, 2005.Siegfried JM, Stabile LP, Liu X, Thomas SM, Grandis JR. Novel pathways for lung cancer therapy. American Association for Cancer Research, Molecular Pathogenesis of Lung Cancer: Opportunities for Translation to the Clinic, 2005.Bhola NE, Zhang Q, Lui VWY, Siwak DR, Xi S, Thomas SM, Ogagan MJ, Gubish CT, Siegfried JM, Mills GB, Grandis JR. Anti-tumor effects of GRPR and EGFR targeting in Head and Neck Squamous Cell Carcinoma. Proceedings of the American Association of Cancer Research, 46: LB-287, 2006.Choi SH, Cai Q, Nozawa H, Thomas SM, Grandis JR. Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma. Proceedings of the American Association of Cancer Research, 46: LB-178, 2006.Thomas SM, Wentzel AL, Zhang Q, Freilino ML, Chan DC, Gooding WE, Siegfried JM, Grandis JR. Prostaglandin E2 and Bradykinin contribute to head and neck squamous cell carcinoma carcinogenesis via EGFR dependent and independent mechanisms. Proceedings of the American Association of Cancer Research, 46:4819, 2006.Nozawa H, Howell G, Zhang Q, Grandis JR, Thomas SM. PLC-1 and c-Src mediate Epidermal Growth Factor Receptor Stimulated Head and Neck Squamous Cell Carcinoma Invasion. Proceedings of the American Association of Cancer Research, 46: 3519, 2006.Lai SY, Lui VW, Koppikar PJ, Thomas SM, Gooding WE, Seethala RR, Branstetter BF, Argiris A and Grandis JR. Intratumoral epidermal growth factor receptor (EGFR) antisense (AS) DNA in recurrent squamous cell carcinoma of the head and neck




(SCCHN): A phase I trial. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition).25 (18S):6009, 2007.Suzuki S, Thomas SM, Morgan S, Grandis JR. EGFRvIII induces HNSCC tumor cell migration and invasion via activation of STAT3. Poster presented at 7th international conference on Head and Neck cancer, July 19-23, 2008, San Francisco, California.Joyce S, Nozawa H, Chiosea S, Grandis JR, Thomas SM. Combined inhibition of PLC -1 and c-Src abrogates Epidermal γGrowth Factor Receptor-mediated head and neck squamous cell carcinoma invasion. Poster presented at the Joint Metastasis Research Society-AACR conference on Metastasis, August 3-7, 2008, Vancouver, BC, Canada. Sun Q, Ming L, Thomas SM, Chen Z, Ferris RL, Grandis JR, Zhang L, Yu J. PUMA modulates the sensitivity to EGFR tyrosine kinase inhibitor in head and neck cancer cells. Proceedings of the American Association of Cancer Research, 2009.Zang Y, Velosa-Rairez C, Thomas SM, Childs EE, Gooding WE, Johnson DE, Grandis JR, Lai SY. STAT3 is critical for the regulation of HIF-1 in head and neck squamous cell carcinoma. Proceedings of the American Association of Cancer Research, 2009.Thomas SM, Rapiredddy S, Sahu B, Joyce S, Ly D. Antisense EGFR guanidium-based peptide nucleic acid (GPNA) oligomers as an antitumor agent for head and neck cancer. AACR-NCI-EORTC International Conference in Molecular targets and Cancer Therapeutics, Boston, MA, November 2009.Kim J, Panahandeh M, Thomas SM. Tumor-associated fibroblasts increase HNSCC invasion in the presence of carcinogen NNK. Proceedings of the American Association of Cancer Research, 2010.Examining the chemopreventive activities of guggulsterone and erlotinib in head and neck squamous cell carcinoma. Leeman-Neill RJ, Seethala RR, Singh SV, Freilino ML, Bednash JS, Thomas SM, Panahandeh MC, Gooding WE, Joyce SJ, Grandis JR. The ASCI/AAP Joint meeting, Chicago, IL, 2010. Development of a transcription factor decoy for efficient systemic administration in head and neck cancer. Sen M, Thomas SM, Ly D, Rapireddy S, Grandis JR. Proceedings of the American Association of Cancer Research, 2010.Tumor-associated fibroblast-induced head and neck squamous cell carcinoma invasion can be abrogated by c-Src and c-Met inhibition. Shi H, Joyce S, Thomas SM. Proceedings of the American Association of Cancer Research, 2011.Paracrine regulation of hepatocyte growth factor production in tumor associated fibroblast by head and neck cancer cells facilitates tumor progression. Joshi R, Lin F, Dasari S, Thorne S, Thomas SM. Cell Symposia: Hallmarks of Cancer, 2012. Guanidinium antisense oligonucleotides for cancer therapy. Thomas SM, Ly D. Proceedings of the American Association of Cancer Research, 2013. Hamilton C, Shelton S, Kakarala K, Thomas SM. Tumor-associated fibroblasts: A new target for cancer treatment. AACR Cellular Heterogeneity in the Tumor Microenvironment Special Conference, San Diego, CA 2014. Vishwakarma V, Cole C, Lee A, Stehno-Bittel L, Thomas SM. Antitumor efficacy of Arum palaestinum extracts against head and neck squamous cell carcinoma. Proceedings of the American Association of Cancer Research, 2015. Kumar D, Kasturi P, Van Houten B, Thomas SM. Tumor associated fibroblasts facilitate head and neck cancer metabolism. Proceedings of the American Association of Cancer Research, 2015.Kandl CJ, Kumar D, Hamilton C, Thomas SM. Inhibition of c-Met effectively mitigates stroma-facilitated HNSCC progression. Combined Otolaryngological Spring Meetings (COSM), 2015. Boston MA.Vishwakarma V, Stehno-Bittel L, Thomas SM. Antitumor efficacy of Arum palaestinum-based formulation GZ17-6.02 in head and neck squamous cell carcinoma. American Head and Neck Society Annual Meeting, 2015, Boston, MA.New J, Vishwakarma V, Kumar D, Crooker K, Snyder V, Shnayder Y, Kakarala K, Tsue T, Girod D, Stehno-Bittel L, Thomas SM. Mechanistic Insights into the antitumor efficacy of nutraceutical GZ17-06.02, a highly effective formulation of Arum Palaestinum Extract on head and neck Squamous cell carcinoma. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Boston, MA.Kumar D, Vishwakarma V, New J, Joshi R, Lim F, Dasari S, Gutierrez W, Leef G, Chavan H, Dai H, Tawfik O, Straub J, Shnayder Y, Kakarala K, Tsue TT, Girod D, Van Houten B, Kasturi P, Thomas SM. Tumor-associated fibroblasts facilitate head and neck cancer glycolysis and growth. American Head and Neck Society Annual Meeting, 2016, Seattle, WA.Kumar D, Vishwakarma V, New J, Joshi R, Lim F, Dasari S, Gutierrez W, Leef G, Chavan H, Dai H, Tawfik O, Straub J, Shnayder Y, Kakarala K, Tsue TT, Girod D, Van Houten B, Kasturi P, Thomas SM. Targeting tumor-stroma metabolic symbiosis for head and neck cancer therapy. Proceedings of the American Association for Cancer Research, 2016, Volume 57, New Orleans, LA. Jones J, Usman S, New J, Le T, Bruegger D, Hoover L, Tawfik O, Thomas SM. The JNA transcriptome: Up regulation of fibroblast growth factor receptor and vascular endothelial growth factor. 2016, SENTAC, Orlando, FL.Snyder V, Standing D, Kumar D, Anant S, Thomas SM. Characterization of DCLK1 as a stem cell marker for head and neck squamous cell carcinoma. 2016 Association for Women Surgeons, Washington, DC.

G. Other Scholarly Publications: Examples include - clinical guidelines, policy documents, position statements or white papers, etc.

4. Presentations and Posters: Presentations and posters should be numbered and in chronological order, oldest to newest.




A. Oral Paper Presentation: List all authors (applicant’s name in BOLD), title, sponsoring organization, extent of peer-review, location and date of presentation.

National and international paper presentations:

07/15 Podium presentation at 5th World Congress of the International Academy of Oral Oncology, Sau Paulo, Brazil. “Molecular Targeting of Paracrine Signaling Between Oral Cancer Cells and Stromal Fibroblasts”. 07/16 Kumar D, Vishwakarma V, New J, Joshi R, Lim F, Dasari S, Gutierrez W, Leef G, Chavan H, Dai H, Tawfik O, Straub J, Shnayder Y, Kakarala K, Tsue TT, Girod D, Van Houten B, Kasturi P, Thomas SM. Tumor-associated fibroblasts facilitate head and neck cancer glycolysis and growth. American Head and Neck Society Annual Meeting, 2016, Seattle, WA.

Local and regional paper presentations:

09/13 Invited speaker at the Department of Pharmacology, Toxicology, University of Kansas Medical Center, Kansas City, KS. “Antisense Gene Therapy Using Guanidinium Peptide Nucleic Acid Oligomers”10/13 Grand Rounds, Department of Otolaryngology, Kansas University Medical Center, Kansas City, KS. “Demystifying Translational Research” 10/13 Invited speaker at the Cancer Biology Monthly Meeting, University of Kansas, Lawrence, KS. “The role of tumor-associated fibroblasts in head and neck cancer progression” 04/15 Poster presented at American Head and Neck Society Translational Research Meeting, Boston, MA. “Antitumor Efficacy of Arum palaestinum-based formulation GZ17 6.02 in Head and Neck Squamous Cell Carcinoma” 10/15 Invited Speaker, University of Kansas Cancer Center Seminar Series, KUMC, KS. “Disrupting tumor-stroma metabolic symbiosis for head and neck cancer therapy”.

B. Poster Presentations:List all authors (applicant’s name in BOLD), title, sponsoring organization, extent of peer-review, and location and date of presentation.

National and international poster presentations:

Kumar D, Vishwakarma V, New J, Chavan H, Kasturi P, Thomas SM. Disrupting tumor-stroma cross-talk for therapeutic benefit in head and neck cancer.2016, Midwest Tumor Microenvironment Meeting, Minneapolis, MN.

Local and regional poster presentations:

New J, Gutierrez W, Leef G, Chavan H, Joshi R, Tawfik O, Shelton SN, Straub J, Lin F, Dasari S, Shnayder Y, Kakarala K, Tsue TT, Girod D, Van Houten B, Kasturi P, Thomas SM. Targeting tumor-stroma metabolic symbiosis for head and neck cancer therapy. 2015, University of Kansas Cancer Center SymposiumNew J, Arnold L, Ananth M, Alvi S, Thomas SM. Secretory autophagy in tumor associated fibroblasts promotes head and neck squamous cell carcinoma progression and emerges as a novel therapeutic target. 2016, Student Research Forum KUMCNew J, Arnold L, Ananth M, Alvi S, Thomas SM. Secretory autophagy in tumor associated fibroblasts promotes head and neck squamous cell carcinoma progression and emerges as a novel therapeutic target. University of Kansas Cancer Center Symposium

C. Invited Seminars at Other Universities and Institutions:Provide title, sponsoring organization or institution, and date of presentation.

National and international seminars:

02/03 Invited speaker at the Winter Lung Cancer Spore Meeting, February, Santa Monica, CA. “Gastrin-releasing peptide-mediated transactivation of epidermal growth factor receptor in cancers of the lung and head and neck”. 07/05 Invited speaker at the 13th SPORE investigators workshop, Washington D.C., “Organotypic models of Squamous Cell Carcinoma of the Head and Neck” 03/06 Invited speaker at the Frontiers in Peptide Nucleic Acid and Related Technologies symposium, Carnegie Mellon University, Pittsburgh, PA. “Antisense EGFR Guanidine-Based Peptide Nucleic Acid (GPNA) Oligomers as an Antitumor Agent for Head and Neck Cancer” 04/06 Invited speaker at the Annual meeting of the American Association for Cancer Research Minisymposium, Washington D.C. “Prostaglandin E2 and Bradykinin contribute to head and neck squamous cell carcinoma carcinogenesis via EGFR dependent and independent mechanisms07/06 Invited speaker at the 14th SPORE investigators workshop, Baltimore, MD, “EGFR Antisense oligonucleotides as a Therapeutic Agent for HNSCC” 07/07 Invited speaker at the 15th SPORE investigators workshop, Baltimore, MD, “Targeting EGFR in lung cancer with EGFR guanidinium antisense peptide nucleic acids” 12/11 Invited speaker at the Fourth International Symposium on Translational Cancer Research: Recent developments in cancer prevention, Udaipur, Rajasthan, India, “Cross-talk between head and neck cancer cells and stromal fibroblasts




facilitates tumor progression” 10/08 Invited speaker at Lung and Thoracic Malignancies Program meeting, Pittsburgh, PA, “Targeting the Epidermal Growth Factor Receptor with Antisense Guanidinium Peptide Nucleic Acid” 06/09 Invited speaker at the Department of Otolaryngology Head and Neck SPORE meeting, Pittsburgh, PA, “Head and Neck Cancer Preclinical Models at the University of Pittsburgh” 05/10 Invited speaker at the Eye and Ear Foundation Scientific Advisory Meeting, Pittsburgh, PA, “Targeting the epidermal growth factor receptor with antisense guanidinium, peptide nucleic acids” 09/11 Invited speaker at the University of Pittsburgh Signaling club, Pittsburgh, PA, “Cross-talk between head and neck cancer cells and stromal fibroblasts-Implications for tumor progression” 12/11 Invited speaker at the Fourth International Symposium on Translational Cancer Research: Recent developments in cancer prevention, Udaipur, Rajasthan, India, “Cross-talk between head and neck cancer cells and stromal fibroblasts facilitates tumor progression” 01/12 Invited speaker at University of Texas San Antonio, San Antonio, TX. “EGFR antisense gene therapy: Progress toward systemic delivery” 02/12 Invited speaker at the Department of Pharmacology and Chemical Biology Seminar Series, University of Pittsburgh, Pittsburgh, PA. “EGFR antisense gene therapy: Progress toward systemic delivery” 10/12 Invited speaker at the Department of Otolaryngology, University of Kansas Medical Center, Kansas City, KS. “Deviant Stroma-Facilitators of head and neck cancer progression” 10/13 Invited speaker at the Department of Otolaryngology, University of Rochester Medical Center, Rochester, NY. “Deviant Stroma-Facilitators of head and neck cancer progression”10/15 Invited speaker at the 102th Indian Science Congress, University of Mumbai, Mumbai, India. “Head and Neck Cancer: Finding the Right Hammer to Crack A Tough Nut”.10/16 Invited speaker at the Indian Institute of Science, Bangalore, India. “Disrupting tumor-stroma metabolic symbiosis for head and neck cancer therapy”.

Local and regional seminars:

10/13 Grand Rounds, Department of Otolaryngology, Kansas University Medical Center, Kansas City, KS. “Demystifying Translational Research”01/14 Invited speaker at the University of Kansas Cancer Center, Cancer Biology Program Meeting, James P Davis Hall, Wyandotte County Lake, Kansas City, KS. “Intratumor-heterogeneity of Head and Neck Cancer”01/14 Invited speaker at the University of Kansas Cancer Center, Cancer Biology Program Meeting, James P Davis Hall, Wyandotte County Lake, Kansas City, KS. “Head and Neck Cancer: A True Team Player”01/14 Invited speaker at 2014 Kansas IDeA Network of Biomedical Research Excellence (K-INBRE) Symposium, Kansas City Marriott Downtown, Kansas City, MO. “Tumor-associated Fibroblasts: The New Target for Cancer Treatment”01/14 Invited speaker at the Department of Anatomy and Cell Biology, University of Kansas Medical Center, Kansas City, KS. “Tumor-associated Fibroblasts: The New Target for Cancer Treatment”03/14 Invited speaker at KU Head and Neck Cancer Support Group, University of Kansas Medical Center, Kansas City, KS. “Head and Neck Cancer Research: Finding the Right Hammer to Crack a Tough Nut”09/14 Podium panelist at the Networking and Career Development Series, Women in Medicine and Sciences (WIMS), KUMC04/15 Invited Speaker, Division of Biology, Kansas State University, Manhattan, KS. “Dynamic Tumor-Stroma Reciprocity Facilitates Disease Progression”.03/16 Invited Speaker, Department of Biochemistry, University of Kansas Medical Center, Kansas City, Kansas. “Targeting tumor-stroma metabolic symbiosis for head and neck cancer therapy”.6/16 Invited Speaker, Secondary Teachers Training in Biomedical Sciences Meeting, Kansas City, Kansas. “Demystifying Translational Research”10/16 Invited Speaker at Collaborate2Cure Seminar Series organized by the Kansas City Life Sciences Institute, Kaufman Foundation Building, Kansas City, Kansas. “Antigen-targeted therapy for head and neck cancer”.02/17 Invited Speaker at Christian Medical College, Vellore, Karnataka, India. “Translational Research in Proliferative disorders of the head and neck”.02/17 Invited Speaker at SRM University, Sonepat, Haryana, India. “Navigating Challenges in Cancer Research”.

03/17 Speaker representing India at a Panel Discussion on “Girls, Women and International Education”. Presented by The National Archives at Kansas City in partnership with The American Association of University Women-KC Chapter.

D. Media Presentations or InterviewsProvide topic, event type (e.g. TV segment, radio interview), sponsoring organization or institution, and date of appearance.

5. Other Evidence of Scholarship:




Include patents or other evidence of acceptance of devices or procedures.

“Antisense EGFRAS guanidinium-peptide nucleic acid (GPNA) oligonucleotides as an antitumor agent”, US Patent Number: 79603600, US Patent Issue Date: 06/14/2011

